TrialSignal
Clinical trial intelligence report
Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01811160
Status
COMPLETED
Phase
Phase 4
Sponsor
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Executive brief
Investment-Ready Snapshot
This clinical trial investigated the effects of melatonin on metabolic side effects in patients treated with second generation antipsychotics for schizophrenia or bipolar disorder. The study aimed to address the significant metabolic risks associated with SGA, which include weight gain and dysregulation of glucose and lipids.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01811160
Indication
Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality
gene therapy
Target
Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
Intervention
Melatonin, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.